natgillin/translations-raw huggingface dataset:
If the pen malfunctions (see instructions for using the pen), the solution may be drawn from the cartridge into a syringe (suitable for an insulin with 100 Units/ml) and injected.
Če se injekcijski peresnik pokvari (glejte navodila za uporabo injekcijskega peresnika), je raztopino mogoče potegniti iz vložka v injekcijsko brizgo (primerno za insulin s 100 enotami/ml) in jo injicirati.
If the pen malfunctions, (see instructions for using the pen) the solution may be drawn from the cartridge into a syringe (suitable for an insulin with 100 Units/ml) and injected.
Če se injekcijski peresnik pokvari, je raztopino mogoče potegniti iz vložka v injekcijsko brizgo (primerno za insulin s 100 enotami/ml) in jo injicirati.
if the percentage of blood leaving your heart each time it contracts is too low (condition called left ventricular dysfunction),
če je delež krvi, ki ga srce iztisne pri vsakem skrčenju, premajhen (to stanje imenujemo moteno delovanje (disfunkcija) levega prekata).
If the person has difficulty breathing, you should prompt the person to breathe in every 5-10 seconds;
Če ima oseba težave z dihanjem, jo morate spodbuditi k dihanju vsakih 5-10 sekund.
If the person has stopped breathing, you should attempt to resuscitate her/him until emergency help arrives.
Če oseba preneha dihati, jo morate poskusiti oživljati do prihoda nujne medicinske pomoči.
If the person to be vaccinated has a blood disorder or any type of cancer that affects the immune system.
Če ima oseba, ki naj bi bila cepljena, bolezen krvi ali katero koli vrsto raka, ki vpliva na imunski sistem.
If the person to be vaccinated has a family history of congenital or hereditary immunodeficiency, unless the immune competence of this person is demonstrated.
Če ima oseba, ki naj bi bila cepljena, v družini prirojeno ali dedno imunsko pomanjkljivost, razen če je bila dokazana imunska sposobnost te osebe.
If the person to be vaccinated has a weakened immune system because of a disease (including AIDS).
Če ima oseba, ki naj bi bila cepljena, zaradi bolezni oslabljen imunski sistem (vključno z AIDS- om).
If the person to be vaccinated has active untreated tuberculosis.
Če ima oseba, ki naj bi bila cepljena, aktivno nezdravljeno tuberkulozo.
If the person to be vaccinated has any illness with fever higher than 38.5°C; however, low- grade fever itself is not a reason to delay vaccination.
Če ima oseba, ki naj bi bila cepljena, kakršno koli bolezen z zvišano telesno temperaturo nad 38,5 °C; malo zvišana telesna temperatura pa sama po sebi ni vzrok, da bi cepljenje odložili.
If the person to be vaccinated is allergic to any of the components of this vaccine (including neomycin or any of the other ingredients listed in section 6).
Če je oseba, ki naj bi bila cepljena, alergična na katero koli sestavino tega cepiva (vključno z neomicinom ali katero koli drugo sestavino, navedeno v poglavju 6).
If the person to be vaccinated is pregnant (in addition, pregnancy should be avoided for 1 month after vaccination, see Pregnancy and breast-feeding).
Če je oseba, ki naj bi bila cepljena, nosečnica (poleg tega 1 mesec po cepljenju ne smete zanositi, glejte Nosečnost in dojenje).
If the person to be vaccinated is receiving treatment or taking medications that may weaken the immune system (except low-dose corticosteroid therapy for asthma or replacement therapy).
Če oseba, ki naj bi bila cepljena, prejema terapijo ali jemlje zdravila, ki lahko oslabijo imunski sistem (razen majhnih odmerkov kortikosteroidov pri astmi ali kot nadomestno zdravljenje).
If the pharmacy compounded suspension is also not available, patients may prepare the suspension from capsules at home.
Če tudi suspenzija, pripravljena v lekarni, ni na voljo, lahko bolnik pripravi suspenzijo iz kapsul doma
If the plastic B cap is loose or missing, do not use the vial.
Če plastični pokrovček ni trdno pričvrščen ali ga ni, viale ne uporabite.
If the platelet counts are excessively increased, discontinue Nplate and monitor platelet counts.
Če se število trombocitov čezmerno poveča, je treba uporabo zdravila Nplate prekiniti in kontrolirati število trombocitov.
If the plunger is stuck or damaged:
Če se je bat zataknil ali je poškodovan:
If the polyuria/polydipsia persists and the Na⁺/K⁺ ratio is >32, then decrease the dose of Zycortal without changing the dosing interval.
Če poliurija/polidipsija vztraja in je razmerje Na⁺/K⁺> 32, odmerek zdravila Zycortal zmanjšajte brez spreminjanja intervala odmerjanja.
If the potent inducer is discontinued, consider a washout period of at least 3 to 5 days (reasonable time for significant enzyme de-induction) before the Votubia dose is returned to the dose used prior to initiation of the co-administration.
Pri ukinitvi zdravljenja z močnim induktorjem je treba upoštevati, da se induktor izloča iz telesa vsaj 3 do 5 dni (sprejemljivo obdobje, v katerem se znatno zmanjša indukcija encima) in po tem času vrniti odmerek zdravila Votubia na odmerek pred začetkom sočasne uporabe.
If the powder for oral suspension is not available, the pharmacist can make up a solution using the contents of Ebilfumin capsules, or the contents of the capsules can be mixed into sweetened food at home.
Če prašek za peroralno suspenzijo ni na voljo, lahko farmacevt pripravi raztopino s pomočjo vsebine kapsul zdravila Ebilfumin; vsebino kapsul pa je mogoče vmešati v sladko hrano tudi doma.
If the powder for oral suspension is not available, the pharmacist can make up a solution using the contents of the capsules, or the contents of the capsules can be mixed into sweetened food at home.
Če prašek za peroralno suspenzijo ni na voljo, lahko farmacevt pripravi raztopino s pomočjo vsebine kapsul; vsebino kapsul pa je mogoče vmešati v sladko hrano tudi doma.
If the pre-filled syringe is not used within 5 minutes of removing the cap, you must dispose of it in a puncture resistant container and use a new pre-filled syringe.
Če napolnjene injekcijske brizge ne uporabimo v 5 minutah po odstranitvi pokrovčka, jo je treba zavreči v zabojnik za ostre predmete, odporen proti vbodom, in uporabiti novo.
If the prepared solution of LeukoScan appears discoloured or contains particles, it should not be used.
Če je pripravljena raztopina zdravila LeukoScan videti razbarvana ali vsebuje delce, ne sme biti uporabljena.
If the product comes into contact with the eyes, rinse immediately with plenty of water.
Če pride zdravilo v stik z očmi, takoj izperite z veliko količino vode.
If the product has been shaken vigorously, don’t use it.
Ne uporabite zdravila, ki je bilo preveč pretreseno.
If the product has been shaken vigorously, don’t use it.
Če je bilo zdravilo izpostavljeno močnemu stresanju, ga ne uporabite.
If the product has not been used for 5 days, it should be re-primed by spraying once.
Če bolnik ni uporabljal zdravila 5 dni, ga je treba reaktivirati z enim pritiskom na sprožilec.
If the product has not been used for a period of more than seven days, the nasal spray must be primed again by actuating once before the next dose is taken.
Če zdravilo ni bilo uporabljeno več kot sedem dni, je treba pred vnosom naslednjega odmerka z enkratnim pritiskom na pršilo sprostiti nekaj zdravila v zrak.
If the product is accidentally self-injected, medical advice should be sought immediately and the package leaflet or label shown to the doctor.
V primeru nenamernega samoinjiciranja zdravila se je treba takoj posvetovati z zdravnikom in mu pokazati navodilo za uporabo ali ovojnino.
If the product is not used immediately, it should be shaken vigorously to re-suspend.
Če zdravila ne uporabite takoj, ga morate močno pretresti, da se ponovno suspendira.
If the product is not used right away, it should be shaken vigorously to re-suspend.
Če zdravila ne uporabimo takoj, ga moramo močno pretresti, da se ponovno suspendira.
If the protective paper is not fully sealed or if it is broken, do not use the vial adapter.
Če zaščitni papir ni povsem prilepljen ali je pretrgan, nastavka za vialo ne uporabite.
If the Provenge bag leaks, is damaged, or if particles or clumps remain in the bag after gentle manual mixing, the product must not be used.
Če vrečka z zdravilom Provenge pušča, je poškodovana ali v njej po nežnem ročnem mešanju ostanejo delci ali grudice, zdravila ne smete uporabiti.
If the pump does not function well, you can draw the insulin from the cartridge into an injection syringe for injection.
Če črpalka ne deluje dobro, lahko insulin iz vložka izvlečete v injekcijsko brizgo.
If the rash persists after 7 days, Esbriet should be discontinued for 15 days, with re-escalation to the recommended daily dose in the same manner as the dose escalation period.
Če izpuščaj po sedmih dneh ne izgine, je treba zdravljenje z zdravilom Esbriet za 15 dni prekiniti, nato pa odmerek postopoma ponovno povečati do priporočenega dnevnega odmerka, tako kot v običajnem obdobju stopnjevanja odmerka.
If the rate of rise in haemoglobin is greater than 2 g/dl (1.24 mmol/l) in one month or if the haemoglobin level is increasing and approaching 12 g/dl (7.45 mmol/l), the dose is to be reduced by approximately 25%.
Če se je koncentracija hemoglobina v enem mesecu povečala za več kot 2 g/dl (1,24 mmol/l) ali če se koncentracija hemoglobina povečuje in približuje 12 g/dl (7,45 mmol/l), odmerek zdravila zmanjšajte za približno 25 %.
If the rate of rise in haemoglobin is greater than 2 g/dl (1.24 mmol/l) over a month or if the haemoglobin level is increasing and approaching 12 g/dl (7.45 mmol/l), the dose is to be reduced by approximately 25%.
Če se je koncentracija hemoglobina v enem mesecu povečala za več kot 2 g/dl (1,24 mmol/l) ali če se koncentracija hemoglobina povečuje in približuje 12 g/dl (7,45 mmol/l), odmerek zmanjšajte za približno 25 %.
If the rate of rise in haemoglobin is greater than 2 g/dl (1.25 mmol/l) in one month or if the haemoglobin level is increasing and approaching 12 g/dl (7.45 mmol/l), the dose is to be reduced by approximately 25 %.
Če se je koncentracija hemoglobina v enem mesecu povečala za več kot 2 g/dl (1,25 mmol/l) ali če se koncentracija hemoglobina povečuje in približuje 12 g/dl (7,45 mmol/l), odmerek zdravila zmanjšajte za približno 25 %.
If the reaction is severe, your doctor will stop the intravenous infusion immediately and start giving you appropriate medical treatment.
Če je reakcija resna, bo vaš zdravnik takoj prekinil intravensko infundiranje in vam začel nuditi ustrezno zdravljenje.
If the reactions are severe and/or there is a loss of effect from this medicine, your doctor will perform a blood test to check for antibodies which may affect the outcome of your treatment
Če so reakcije resne in/ali pride do izgube učinka tega zdravila, bo zdravnik opravil krvno preiskavo, s katero bo preveril protitelesa, ki lahko vplivajo na izid vašega zdravljenja.
If the recommended schedule cannot be followed exactly, the interval between the first two doses should be approximately two months and the interval between the second and third dose should be as close as possible to eight to eleven months.
Če priporočene sheme ni mogoče natančno upoštevati, mora biti presledek med prvima odmerkoma približno dva meseca, presledek med drugim in tretjim odmerkom pa čim bliže osmim do enajstim mesecem starosti.
If the reconstituted product is not administered immediately, storage times and conditions prior to use are in the responsibility of the user.
Če zdravila ne damo takoj, je za trajanje in pogoje shranjevanja pred uporabo odgovoren uporabnik.
If the reconstituted product is not administered immediately, storage times and conditions prior to use are the responsibility of the the user and should not exceed 24 hours at 2 to 8 °C.
Če zdravila ne damo takoj, je za čas in pogoje shranjevanja pred uporabo odgovoren uporabnik in ne bi smeli trajati dlje kot 24 ur pri 2 °C do 8 °C.
If the reconstituted solution is not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.
Če se rekonstituirane raztopine ne porabi takoj, je za čas in pogoje shranjevanja zdravila po rekonstituciji odgovoren uporabnik.
If the remaining volume is less than the prescribed dose volume, DO NOT use the syringe and contact your healthcare provider.
Če je preostala količina manjša od količine predpisanega odmerka, brizge, NE UPORABITE in se posvetujte s svojim zdravnikom.
If the rise in haemoglobin is greater than 2 g/dl (1.25 mmol/l) in 4 weeks, the dose should be reduced by 25 to 50%.
Če se koncentracija hemoglobina v 4 tednih zviša za več kot 2 g/dl (1,3 mmol/l), je odmerek treba zmanjšati za 25 do 50 %.
If the rise in haemoglobin is greater than 2 g/dl (1.25 mmol/l) in 4 weeks, the dose should be reduced by 25 to 50%.
Če se koncentracija hemoglobina v 4 tednih zviša za več kot 20 g/dl (1,25 mmol/l), je odmerek treba zmanjšati za 25 do 50 %.
If the rise in haemoglobin is greater than 2 g/dl (1.25 mmol/l) in 4 weeks, the dose should be reduced by 25 to 50%.
Če se koncentracija hemoglobina v 4 tednih zviša za več kot 20 g/l (1,25 mmol/l), je odmerek treba zmanjšati za 25 do 50 %.
If the rise in haemoglobin is greater than 2 g/dl (1.25 mmol/l) in 4 weeks, the dose should be reduced by 25 to 50%.
Če se koncentracija hemoglobina v 4 tednih zviša za več kot 20 g/l (1,3 mmol/l), je odmerek treba zmanjšati za 25 do 50 %.
If the rise in haemoglobin is greater than 2 g/dl (1.25 mmol/l) in four weeks reduce the dose by approximately 25%, depending on the rate of increase.
Če se hemoglobin zviša za več kot 2,0 g/dl (1,25 mmol/l) v štirih tednih, odmerek zmanjšajte za približno 25 %, odvisno od hitrosti zvišanja hemoglobina.
If the rise in haemoglobin is greater than 2 g/dl (1.25 mmol/l) in four weeks reduce the dose by approximately 25%.
Če se hemoglobin v štirih tednih zviša za več kot 20 g/l (1,25 mmol/l), zmanjšajte odmerek za približno 25 %, odvisno od hitrosti zvišanja.
If the rise in haemoglobin is greater than 2 g/dl (1.25 mmol/l) in four weeks reduce the dose by approximately 25%.
Če se hemoglobin v štirih tednih zviša za več kot 20 g/l (1,25 mmol/l), zmanjšajte odmerek za približno 25 %.
If the safety test is successful OptiSet is ready for use.
Če je varnostni preizkus uspešen, je OptiSet pripravljen za uporabo.
If the same adverse drug reaction occurs following the switch to alternate daily dosing and does not improve, consider discontinuing treatment with Odomzo.
Če se po prehodu na odmerjanje zdravila vsak drugi dan isti neželeni učinek ponovi oziroma ne pride do izboljšanja, je treba razmisliti o prekinitvi zdravljenja z zdravilom Odomzo.
If the same line has to be used, this line (including Y-line) must be flushed thoroughly with a 0.9 % sodium chloride or 5 % glucose solution before and after the Rapilysin injection.
Če je nujno uporabiti isti kanal, je treba ta kanal (vključno z Y-kanalom) temeljito izprati z 0,9 % fiziološko raztopino ali 5 % raztopino glukoze pred injiciranjem zdravila Rapilysin in po njem.
If the sample tube remains open for more than 30 seconds, the result could be inaccurate.
Če ostane epruveta odprta dlje kot 30 sekund, bo rezultat testa morda nenatančen.
if the seal is broken,
če je tesnilo poškodovano,
If the second and third characters are A7, the manufacturer is Novo Nordisk Production SAS, 45 Avenue d’Orléans, F-28000 Chartres, France.
Če sta drugi in tretji znak A7, je izdelovalec Novo Nordisk Production SAS, 45 Avenue d’Orléans, F-28000 Chartres, Francija.
If the second and third characters are H7 or T6, the manufacturer is Novo Nordisk Production SAS, 45 Avenue d’Orléans F-28000 Chartres, France.
Če sta drugi in tretji znak H7 ali T6, je izdelovalec Novo Nordisk Production SAS, 45 Avenue d’Orléans F-28000 Chartres, Francija.
If the second and third characters are H7 or T6, the manufacturer is Novo Nordisk Production SAS, 45 Avenue d’Orléans, F-28000 Chartres, France.
Če sta drugi in tretji znak H7 ali T6, je izdelovalec Novo Nordisk Production SAS, 45 Avenue d’Orleans, F-28000 Chartres, Francija.
If the second and third characters are H7 or T6, the manufacturer is Novo Nordisk Production SAS, 45 Avenue d’Orléans, F-28000 Chartres, France.
Če sta drugi in tretji znak H7 ali T6, je izdelovalec Novo Nordisk Production SAS, 45 Avenue d’Orléans F-28000 Chartres, Francija.
If the second and third characters are H7 or T6, the manufacturer is Novo Nordisk Production SAS, 45 Avenue d’Orléans, F-28000 Chartres, France.
Če sta drugi in tretji znak H7 ali T6, je izdelovalec Novo Nordisk Production SAS, 45 Avenue d’Orléans, F-28000 Chartres, Francija.
If the second and third characters are S6 or ZF, the manufacturer is Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark
Če sta drugi in tretji znak S6 ali ZF, je izdelovalec Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd, Danska.
If the second and third characters are S6 or ZF, the manufacturer is Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark.
Če sta drugi in tretji znak S6 ali ZF, je izdelovalec Novo Nordisk A/S, Novo Allé, DK- 2880 Bagsvaerd, Danska.
If the second and third characters are S6 or ZF, the manufacturer is Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark.
Če sta drugi in tretji znak S6 ali ZF, je izdelovalec Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd, Danska.
If the second and third characters are S6, P5, K7, R7, VG, FG or ZF, the manufacturer is Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark.
Če sta drugi in tretji znak S6, P5, K7, R7, VG, FG ali ZF, je izdelovalec Novo Nordisk A/S Novo Allé, DK-2880 Bagsvaerd, Danska.
If the second and third characters are S6, P5, K7, R7, VG, FG or ZF, the manufacturer is Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark.
Če sta drugi in tretji znak S6, P5, K7, R7, VG, FG ali ZF, je izdelovalec Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd, Danska.
If the second infusion has been completed without a severe adverse reaction, the remaining infusions (3-12) should be administered over 4 hours (see section 4.2 of the SmPC), through a peripheral line or indwelling catheter, according to the schedule below:
Če se je drugo infundiranje končalo brez hude reakcije, je treba preostale infuzije (3-12) dati v 4 urah (glejte poglavje 4.2 povzetka glavnih značilnosti zdravila) po perifernem kanalu ali stalnem katetru in po naslednjem časovnem razporedu:
If the second infusion has been completed without a severe adverse reaction, the remaining infusions (3-12) should be administered over 4 hours (see section 4.2), through a peripheral line or indwelling catheter, according to the schedule below:
Če se je drugo infundiranje končalo brez hude reakcije, je treba preostale infuzije (3-12) dati v 4 urah (glejte poglavje 4.2) po perifernem kanalu ali stalnem katetru in po naslednjem časovnem razporedu:
If the second infusion has been completed without severe infusion related ADRs, the remaining infusions can start at a rate of 25 ml/hour and should be increased every 30 minutes up to a maximum of 400 ml/hour (see section 6.6).
Če se je drugo infundiranje končalo brez hudih z infundiranjem povezanih neželenih učinkov zdravila, je mogoče preostala infundiranja začeti s hitrostjo 25 ml/uro, hitrost pa vsakih 30 minut povečati, do največ 400 ml/uro (glejte poglavje 6.6).
If the second vaccine dose is administered earlier than 5 months after the first dose, a third dose should always be administered.
Če se z drugim odmerkom cepiva cepi prej kot 5 mesecev po prvem odmerku, je treba vedno cepiti še s tretjim odmerkom.
If the second vaccine dose is administered earlier than 6 months after the first dose, a third dose should always be administered.
Oseba, ki je prejela drugi odmerek prej kot v šestih mesecih po prejemu prvega odmerka, mora vedno prejeti tudi tretji odmerek.
If the seizure does not stop within 10 minutes, call an ambulance.
Če epileptični napad v 10 minutah ne mine, pokličite reševalce.
If the signs and symptoms of disease recur, Flixabi can be re-administered within 16 weeks following the last infusion.
Če se znaki in simptomi bolezni ponovijo, lahko zdravilo Flixabi ponovno uporabite v roku 16 tednov po zadnji infuziji.
If the signs and symptoms of disease recur, infliximab can be re-administered within 16 weeks following the last infusion.
Če se znaki in simptomi bolezni ponovijo, lahko infliksimab ponovno uporabite v roku 16 tednov po zadnji infuziji.
If the solution for injection contains particulate matter or if it is any colour other than clear colourless, the pre-filled pen must not be used.
Napolnjenega injekcijskega peresnika ne smete uporabljati, če vsebuje raztopina za injiciranje trdne delce ali če ni bistra in brezbarvna.
If the solution is any colour except colourless or slightly yellow, or if you can see particles floating in it, do not inject.
Če je raztopina kakršne koli druge barve, razen brezbarvna ali rahlo rumena, ali če v njej plavajo delci, je ne injicirajte.
If the solution is cloudy, or contains particulate matter, it must not be injected (see section 4.2).
Če je raztopina motna ali vsebuje delce, je ne smete injicirati (glejte poglavje 4.2).
If the solution is cloudy, or contains particulate matter, it must not be injected (see section 6.6).
Če je raztopina motna ali vsebuje delce, je ne smete injicirati (glejte poglavje 6.6).
If the solution is coloured, cloudy or you can see particles floating in it.
Raztopina je obarvana, motna ali v njej plavajo delci.
If the solution is discoloured or contains particles, discard it and start again with a syringe and vial out of your package.
Če je raztopina obarvana ali vsebuje delce, jo zavrzite in postopek začnite znova z novim paketom.
If the solution is given into a vein, it should be injected over 1-5 minutes.
Če se raztopino daje v veno, naj injiciranje traja 1 – 5 minut.
If the solution is not clear and colourless it should be discarded.
Če raztopina ni bistra in brezbarvna, jo je treba zavreči.
If the solution is not used immediately, it should be stored in a refrigerator at 2°C – 8°C.
Če raztopine ne uporabite takoj, jo je treba shraniti v hladilnik pri temperaturi 2 °C  8 °C.
If the solution is not used immediately, storage prior to use is the responsibility of the user and should be in a refrigerator at 2 °C – 8 °C.
Če zdravstveni delavec raztopine ne uporabi takoj, je sam odgovoren za trajanje in pogoje shranjevanja pred uporabo in mora biti v hladilniku pri 2 ºC8 ºC.
If the solution is not used immediately, storage prior to use is the responsibility of the user and should be in a refrigerator at 2°C – 8°C.
Če zdravstveni delavec raztopine ne uporabi takoj, je sam odgovoren za trajanje in pogoje shranjevanja pred uporabo, raztopina mora biti shranjena v hladilniku pri 2 °C – 8 °C.
If the solution looks cloudy, do not use the pen.
Če je raztopina motna, injekcijskega peresnika ne smete uporabiti.
if the solvent is not pulled into the vial (this indicates loss of vacuum in the vial, so the powder must not be used).
če se vehikel ni prenesel v vialo (to pomeni, da v viali ni bilo vakuuma, zato praška ne smete uporabiti);
If the spray has not been used within 5 days after priming it should be discarded.
Če po aktivaciji pršila niste uporabljali 5 dni, ga morate zavreči.
If the spray is blocked, aim the spray away from you (and any other people) and push firmly down on the pump.
Če je pršilo blokirano, usmerite razpršilno šobo proč od sebe (in drugih ljudi) in čvrsto pritisnite na črpalko.
If the starting dose is well-tolerated, the dose can be titrated up to a maximum of 1,000-1,200 mg daily (1,000 mg for patients weighing < 75 kg and 1,200 mg for patients weighing ≥ 75 kg).
Če bolnik začetni odmerek dobro prenaša, ga je mogoče povečevati do največ 1.000–1.200 mg na dan (1.000 mg za bolnike s telesno maso < 75 kg in 1.200 mg za bolnike s telesno maso ≥ 75 kg).
If the status light flashes alternately green and orange instead of orange only please refer immediately to section 7.4.
Če lučka izmenično utripa zeleno in oranžno, namesto samo oranžno, takoj poglejte točko 7.4.
If the strict diet does not adequately reduce phenylalanine amount in your blood your doctor will consider whether you must take this medicine.
Če se s strogo dieto raven fenilalanina v krvi ne zniža ustrezno, bo vaš zdravnik premislil, ali morate uporabljati to zdravilo.